Hope For Postpartum Depression: This Company To Launch Clinical Trial On Next-Gen Psychedelic - Mindset Pharma (OTC:MSSTF)
Clinical-stage biopharma company Reunion Neuroscience has received the FDA’s clearance on its Investigational New Drug (IND) application to begin a Phase 2 study of RE104, a novel serotonergic psychedelic compound aimed at treating postpartum depression (PPD.) 
Source: benzinga.com